Affordable Access

Access to the full text

Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

Authors
  • Schumacher-Schuh, Artur1, 2
  • Bieger, Andrei3
  • Borelli, Wyllians V.2
  • Portley, Makayla K.4
  • Awad, Paula Saffie5
  • Bandres-Ciga, Sara4, 6
  • 1 Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Porto Alegre , (Brazil)
  • 2 Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre , (Brazil)
  • 3 Department of Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre , (Brazil)
  • 4 Neurodegenerative Disorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD , (United States)
  • 5 Movement Disorders Clinic, Centro de Trastornos de Movimiento (CETRAM), Santiago , (Chile)
  • 6 Laboratory of Neurogenetics, Molecular Genetics Section, National Institute on Aging, National Institutes of Health, Bethesda, MD , (United States)
Type
Published Article
Journal
Frontiers in Neurology
Publisher
Frontiers Media SA
Publication Date
Jan 31, 2022
Volume
12
Identifiers
DOI: 10.3389/fneur.2021.792227
Source
Frontiers
Keywords
Disciplines
  • Neurology
  • Review
License
Green

Abstract

Proteomics and metabolomics are two emerging fields that hold promise to shine light on the molecular mechanisms causing neurodegenerative diseases. Research in this area may reveal and quantify specific metabolites and proteins that can be targeted by therapeutic interventions intended at halting or reversing the neurodegenerative process. This review aims at providing a general overview on the current status of proteomic and metabolomic profiling in neurodegenerative diseases. We focus on the most common neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. We discuss the relevance of state-of-the-art metabolomics and proteomics approaches and their potential for biomarker discovery. We critically review advancements made so far, highlighting how metabolomics and proteomics may have a significant impact in future therapeutic and biomarker development. Finally, we further outline technologies used so far as well as challenges and limitations, placing the current information in a future-facing context.

Report this publication

Statistics

Seen <100 times